Trial Profile
Phase II Study of Lapatinib and Capecitabine in 2nd Line Treatment of Locally Advanced/Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 23 Mar 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 18 Aug 2009 Status changed from not yet recruiting to recruiting.
- 14 Apr 2009 New trial record